In the Journals

Pembrolizumab induces durable responses in relapsed, refractory primary mediastinal large B-cell lymphoma

November 14, 2019
Pembrolizumab appeared to be associated with high response rates, durable activity and manageable toxicity among patients with relapsed or refractory…
Meeting News

Sitravatinib plus nivolumab safe, active in advanced urothelial carcinoma

November 13, 2019
NATIONAL HARBOR, Md. — The combination of sitravatinib and nivolumab induced encouraging clinical activity among patients with advanced…
FDA News

FDA grants priority review, breakthrough therapy designation to Opdivo-Yervoy combination for HCC

November 11, 2019
The FDA granted the combination of nivolumab and ipilimumab priority review and breakthrough therapy designation for the treatment of patients with…

Avelumab maintenance fails to extend OS in advanced gastric, gastroesophageal junction cancers

November 11, 2019
A randomized phase 3 trial designed to evaluate avelumab as first-line maintenance therapy for patients with unresectable, locally advanced or…
Meeting News

Novel bispecific immune cell engager safe, clinically beneficial in HER2-positive tumors

November 10, 2019
NATIONAL HARBOR, Md. — An investigational bispecific T-cell engager appeared safe and demonstrated some clinical activity among patients with…
Meeting News

Autologous antigen-loaded vaccine safe, feasible for neuroblastoma

November 9, 2019
NATIONAL HARBOR, Md. — An investigational vaccine of autologous dendritic cells loaded with autologous tumor antigens was safe and feasible as…
Meeting News

Front-line atezolizumab improves overall survival in advanced NSCLC

November 9, 2019
NATIONAL HARBOR, Md. — Patients who received atezolizumab as first-line monotherapy for metastatic non-small-cell lung cancer showed…
Meeting News

Off-the-shelf natural killer cells safe, clinically active for advanced Merkel cell carcinoma

November 8, 2019
NATIONAL HARBOR, Md. — Allogeneic activated natural killer cell therapy resulted in some antitumor activity with no serious side effects in…
Meeting News

Anti-CD73 antibody agent appears safe, shows promise in advanced cancers

November 8, 2019
NATIONAL HARBOR, Md. — An investigational anti-CD73 antibody appeared safe and demonstrated promising antitumor activity among patients with…

University of Chicago professor receives ESMO Award for Immuno-Oncology

November 7, 2019
Thomas Gajewski, MD, PhD, will receive this year's ESMO Award for Immuno-Oncology. The award recognizes Gajewski’s work exploring why some…